C4 Therapeutics (CCCC) vs Prelude Therapeutics (PRLD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 177.9% versus a gain of 31.1%. Over five years, PRLD leads with a -76.1% price change compared with -92.8% for CCCC. C4 Therapeutics is the larger company by market cap ($388.8 million vs $310.4 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | PRLD |
|---|---|---|
| Share price | $3.16 | $3.89 |
| Market cap | $388.76M | $310.44M |
| 1-day change | +10.88% | +0.26% |
| YTD return | +65.45% | +34.14% |
| 1-year return | +31.12% | +177.86% |
| 5-year return | -92.80% | -76.14% |
| EPS (TTM) | $-1.01 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $6.83 |
| 52-week low | $1.69 | $1.16 |
| Distance from 52-week high | -38.88% | -43.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +306.96% | +136.50% |
| Average volume | 2.38M | 477.67K |
| Shares outstanding | 123.03M | 65.08M |
| Employees | 104 | 79 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed CCCC by 146.7 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Healthcare · Biotechnology · 79 employees
CCCC vs PRLD FAQ
Which is bigger, C4 Therapeutics or Prelude Therapeutics?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $388.76M compared with $310.44M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, CCCC or PRLD?
PRLD returned +177.86% over the past 12 months, compared with +31.12% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Prelude Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.